We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
Read MoreHide Full Article
Key Takeaways
Vertex is diversifying beyond CF with a kidney disease franchise targeting underlying disease mechanisms.
Povetacicept is advancing in IgAN and pMN, with an FDA decision expected on Nov. 30, 2026.
Inaxaplin's AMPLITUDE study is expected to complete enrollment this year, with interim data due in early 2027.
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has established a dominant position in the cystic fibrosis (CF) market through its portfolio of CFTR modulators, including Trikafta/Kaftrio and the newer Alyftrek. Vertex’s marketed CF therapies are currently used by nearly three-quarters of the approximately 97,000 people with CF across the United States, Europe, Australia and Canada, while its CFTR modulators are capable of treating roughly 95% of people with CF in its core markets. This entrenched leadership has made CF the cornerstone of Vertex’s business and continues to generate substantial cash flows, supported by new patient initiations, label expansions, geographic penetration and the rollout of Alyftrek.
However, given the company’s already extensive penetration of the CF population, building sizable franchises outside CF is increasingly important for sustaining strong long-term growth. Kidney disease represents one of Vertex’s most promising diversification opportunities. The company is building one of the most differentiated kidney disease franchises in biotech by targeting the underlying biological mechanisms of multiple kidney disorders, rather than merely treating symptoms or slowing disease progression.
The company's renal portfolio currently consists of key pipeline candidates like VX-407 for autosomal dominant polycystic kidney disease (ADPKD), inaxaplin for APOL1-mediated kidney disease (AMKD) and povetacicept for IgA nephropathy (IgAN) and primary membranous nephropathy (pMN). It is believed that povetacicept and inaxaplin represent significant commercial opportunities.
Povetacicept was added to Vertex’s portfolio through its approximately $4.9 billion acquisition of Alpine Immune Sciences in 2024. Vertex believes povetacicept has pipeline-in-a-product potential for B-cell-mediated diseases. Povetacicept is designed to target two cytokines, namely BAFF and APRIL, which play key roles in the pathogenesis of multiple B-cell-mediated autoimmune diseases.
Data from the RAINIER study showed that povetacicept led to a rapid, deep and sustained improvement in proteinuria (excess protein in the urine), a direct consequence of IgAN. In June 2026, the FDA accepted the regulatory filing seeking approval for povetacicept for IgAN. A final decision from the FDA is expected on Nov. 30, 2026. This will be an important catalyst for the stock.
If approved, povetacicept would become Vertex's first marketed nephrology product. The commercial opportunity is substantial. Vertex estimates roughly 330,000 people with IgAN in the United States and Europe and more than 1.5 million diagnosed patients globally. Vertex is also conducting a pivotal phase II/III study of povetacicept for pMN and a phase II study for the treatment of gMG.
With potential approvals in IgAN and pMN, povetacicept could emerge as a major growth driver for Vertex, with analysts forecasting blockbuster sales and peak annual revenues in the multi-billion-dollar range.
Inaxaplin is being developed in a phase II/III study (AMPLITUDE) in patients with primary AMKD. Enrollment in the study is complete, with interim data expected in early 2027.
Vertex is also conducting another phase II proof-of-concept study (AMPLIFIED) of inaxaplin in patients with AMKD and other comorbidities like moderate proteinuria and type II diabetes. Data from this study were announced earlier this week, which showed that in patients with AMKD with modest proteinuria, treatment with inaxaplin led to a 42.7% reduction in urine albumin to creatinine ratio (UACR) at week 13 compared to baseline — the study’s primary endpoint. UACR is a urine test that measures the amount of albumin relative to creatinine to assess kidney damage. In patients with AMKD and type II diabetes, inaxaplin led to a reduction in UACR of 17.3%
Potential Competition for Povetacicept in IgAN
There is significant opportunity but IgAN has become considerably more competitive. The FDA has already approved multiple targeted treatments, including Otsuka's monthly APRIL inhibitor Voyxact (sibeprenlimab), Vera Therapeutics' (VERA - Free Report) weekly BAFF/APRIL inhibitor Trutakna (atacicept) and Novartis' (NVS - Free Report) oral endothelin-A receptor antagonist Vanrafia (atrasentan),
VRTX’s Price, Valuation and Estimates
Vertex stock has risen 13.9% so far this year, slightly outperforming the industry’s 12.7% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Vertex is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 25.78 forward earnings, higher than 18.24 for the industry. The stock is also trading above its five-year mean of 25.39.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has declined from $19.17 per share to $18.86 per share over the past 60 days, while that for 2027 has deteriorated from $20.97 per share to $20.46 per share over the same time frame.
View the Zacks #1 Rank List
Image: Bigstock
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
Key Takeaways
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) has established a dominant position in the cystic fibrosis (CF) market through its portfolio of CFTR modulators, including Trikafta/Kaftrio and the newer Alyftrek. Vertex’s marketed CF therapies are currently used by nearly three-quarters of the approximately 97,000 people with CF across the United States, Europe, Australia and Canada, while its CFTR modulators are capable of treating roughly 95% of people with CF in its core markets. This entrenched leadership has made CF the cornerstone of Vertex’s business and continues to generate substantial cash flows, supported by new patient initiations, label expansions, geographic penetration and the rollout of Alyftrek.
However, given the company’s already extensive penetration of the CF population, building sizable franchises outside CF is increasingly important for sustaining strong long-term growth. Kidney disease represents one of Vertex’s most promising diversification opportunities. The company is building one of the most differentiated kidney disease franchises in biotech by targeting the underlying biological mechanisms of multiple kidney disorders, rather than merely treating symptoms or slowing disease progression.
The company's renal portfolio currently consists of key pipeline candidates like VX-407 for autosomal dominant polycystic kidney disease (ADPKD), inaxaplin for APOL1-mediated kidney disease (AMKD) and povetacicept for IgA nephropathy (IgAN) and primary membranous nephropathy (pMN). It is believed that povetacicept and inaxaplin represent significant commercial opportunities.
Povetacicept was added to Vertex’s portfolio through its approximately $4.9 billion acquisition of Alpine Immune Sciences in 2024. Vertex believes povetacicept has pipeline-in-a-product potential for B-cell-mediated diseases. Povetacicept is designed to target two cytokines, namely BAFF and APRIL, which play key roles in the pathogenesis of multiple B-cell-mediated autoimmune diseases.
Data from the RAINIER study showed that povetacicept led to a rapid, deep and sustained improvement in proteinuria (excess protein in the urine), a direct consequence of IgAN. In June 2026, the FDA accepted the regulatory filing seeking approval for povetacicept for IgAN. A final decision from the FDA is expected on Nov. 30, 2026. This will be an important catalyst for the stock.
If approved, povetacicept would become Vertex's first marketed nephrology product. The commercial opportunity is substantial. Vertex estimates roughly 330,000 people with IgAN in the United States and Europe and more than 1.5 million diagnosed patients globally. Vertex is also conducting a pivotal phase II/III study of povetacicept for pMN and a phase II study for the treatment of gMG.
With potential approvals in IgAN and pMN, povetacicept could emerge as a major growth driver for Vertex, with analysts forecasting blockbuster sales and peak annual revenues in the multi-billion-dollar range.
Inaxaplin is being developed in a phase II/III study (AMPLITUDE) in patients with primary AMKD. Enrollment in the study is complete, with interim data expected in early 2027.
Vertex is also conducting another phase II proof-of-concept study (AMPLIFIED) of inaxaplin in patients with AMKD and other comorbidities like moderate proteinuria and type II diabetes. Data from this study were announced earlier this week, which showed that in patients with AMKD with modest proteinuria, treatment with inaxaplin led to a 42.7% reduction in urine albumin to creatinine ratio (UACR) at week 13 compared to baseline — the study’s primary endpoint. UACR is a urine test that measures the amount of albumin relative to creatinine to assess kidney damage. In patients with AMKD and type II diabetes, inaxaplin led to a reduction in UACR of 17.3%
Potential Competition for Povetacicept in IgAN
There is significant opportunity but IgAN has become considerably more competitive. The FDA has already approved multiple targeted treatments, including Otsuka's monthly APRIL inhibitor Voyxact (sibeprenlimab), Vera Therapeutics' (VERA - Free Report) weekly BAFF/APRIL inhibitor Trutakna (atacicept) and Novartis' (NVS - Free Report) oral endothelin-A receptor antagonist Vanrafia (atrasentan),
VRTX’s Price, Valuation and Estimates
Vertex stock has risen 13.9% so far this year, slightly outperforming the industry’s 12.7% growth.
From a valuation standpoint, Vertex is slightly expensive. Going by the price/earnings ratio, the company’s shares currently trade at 25.78 forward earnings, higher than 18.24 for the industry. The stock is also trading above its five-year mean of 25.39.
The Zacks Consensus Estimate for 2026 earnings has declined from $19.17 per share to $18.86 per share over the past 60 days, while that for 2027 has deteriorated from $20.97 per share to $20.46 per share over the same time frame.
Vertex has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.